Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00268125
Recruitment Status : Completed
First Posted : December 22, 2005
Last Update Posted : March 18, 2009
Information provided by:
Institut Claudius Regaud

Brief Summary:
The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.

Condition or disease Intervention/treatment Phase
Breast Neoplasms Device: Acupression's bracelet Behavioral: Hygiene and dietetic advices Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 347 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.
Study Start Date : February 2006
Primary Completion Date : December 2007
Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Reduction of 15% of stage III/IV nausea and vomiting's incidence.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Woman
  • Age > 18 years
  • Well-informed written consent, signed by the patient before the beginning of the study
  • Breast cancer's diagnosis (operated or not)
  • Forecast of a treatment by FEC100 chemotherapy's sort (D1=D21) during at least 3 cycles.
  • Patient affiliated at a welfare or beneficiary from it
  • Investigator estimates that the patient is able to conform with protocol's conditions and to respect them

Exclusion Criteria:

  • Operated arm's lymphedema
  • Wrist's morphology which cannot permit the bracelet's wearing (20 cm)
  • D1=D15 FEC100's treatment
  • Psychic incapability to sign a well-informed consent
  • Refusal to give a written consent
  • Patient under tutelage or guardianship
  • Pregnant or breast-feeding woman
  • Any clinical trial's participation which would impose nausea and vomiting's treatment modalities

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00268125

Centre Oscar Lambret
Lille, France
Centre Paul STRAUSS
Strasbourg, France
Institut Claudius Regaud
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
Principal Investigator: Jean-Pierre DELORD, Dr Institut Claudius Regaud

Responsible Party: Dr Jean-Pierre DELORD, Institut Claudius Regaud Identifier: NCT00268125     History of Changes
Other Study ID Numbers: 05 DIVE 05
First Posted: December 22, 2005    Key Record Dates
Last Update Posted: March 18, 2009
Last Verified: March 2009

Keywords provided by Institut Claudius Regaud:
Breast Neoplasm

Additional relevant MeSH terms:
Breast Neoplasms
Signs and Symptoms, Digestive
Signs and Symptoms
Neoplasms by Site
Breast Diseases
Skin Diseases